# DOLUTEGRAVIR; TENOFOVIR DISOPROXIL FUMARATE; LAMIVUDINE
> **NDA217016** · New Drug Application · Sponsor: STRIDES PHARMA · Approved 2023-09-14
## Drug
- **FDA Application Number:** NDA217016
- **Application type:** New Drug Application
- **Brand name:** DOLUTEGRAVIR; TENOFOVIR DISOPROXIL FUMARATE; LAMIVUDINE
- **Generic name:** Dolutegravir
- **Active ingredients:** DOLUTEGRAVIR; TENOFOVIR DISOPROXIL FUMARATE; LAMIVUDINE
- **Dosage form:** TABLET
- **Route:** ORAL
- **Marketing status:** None (Tentative Approval)
- **Sponsor:** STRIDES PHARMA
- **First approval:** 2023-09-14
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217016)
---
*MORVS · CC0 1.0*